The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin

Journal of Clinical Investigation

Volumn 118, Issue 4, 2008, Pages 1367-1379

  Kenny, Hilary A ^a   Kaur, Swayamjot ^a   Coussens, Lisa M ^b   Lengyel, Ernst ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRONECTIN; GELATINASE A; MESSENGER RNA; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL ADHESION; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; OMENTUM; OVARY CANCER; PERITONEUM; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ABDOMINAL CAVITY; ANIMALS; ANTIBODIES; CELL ADHESION; CELLS, CULTURED; COCULTURE TECHNIQUES; FEMALE; FIBRONECTINS; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, KNOCKOUT; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PROTEASE INHIBITORS; SURVIVAL RATE; TRANSCRIPTION, GENETIC; VITRONECTIN;

EID: 41849105806     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI33775     Document Type: Article

References (55)

1. Cannistra, S.A. 2004. Cancer of the ovary. N. Engl. J. Med. 351:2519-2529.
2. Doig, T., and Monaghan, H. 2006. Sampling the omentum in ovarian neoplasia: when one block is enough. Int. J. Gynecol. Cancer. 16:36-40.
3. Egeblad, M., and Werb, Z. 2002. ?ew functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer. 2:161-174.
4. Liotta, L., Abe, S., Robey, P., and Martin, G. 1979. Preferential digestion of basement membrane collagen by an enzyme derived from a metastatic murine tumor. Proc. Natl. Acad. Sci. U. S. A. 76:2268-2272.
5. Lakka, S.S., et al. 2003. Synergistic down-regulation of urokinase plasminogen activator receptor and matrix metalloproteinase-9 in SNB19 glioblastoma cells efficiently inhibits glioma cell invasion, angiogenesis and tumor growth. Cancer Res. 63:2454-2461.
6. Chantrain, C.F., et al. 2004. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res. 64:1675-1686.
7. Bergers, G., et al. 2000. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2:737-744.
8. Bissett, D., et al. 2005. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J. Clin. Oncol. 23:842-849.
9. Bramhall, S.R., Rosemurgy, A., Brown, P.D., Bowry, C., and Buckels, J.A.C. 2001. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J. Clin. Oncol. 19:3447-3455.
10. Bramhall, S.R., et al. 2002. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br. J. Cancer. 86:1864-1870.
11. Fletcher, L. 2000. MMPI demise spotlights target choice. Nat. Biotechnol. 18:1138-1139.
12. Coussens, L., Fingleton, B., and Matrisian, L.M. 2002. Matrix metalloproteinase inhibitors and cancer: trial and tribulations. Science. 295:2387-2392.
13. Davies, B., Brown, P.D., East, N., Crimmin, M.J., and Balkwill, F. 1993. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res. 53:2087-2091.
14. Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., and Hanahan, D. 1999. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 284:808-812.
15. Giavazzi, R., et al. 1998. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin. Cancer Res. 4:985-992.
16. Watson, S.A., et al. 1999. Inhibition of tumor growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA. Br. J. Cancer. 81:19-23.
17. Lengyel, E., et al. 2001. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol. Oncol. 82:291-298.
18. Schmalfeldt, B., et al. 2001. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin. Cancer Res. 7:2396-2404.
19. Moser, T.L., Pizzo, S.V., Bafetti, L., Fishman, D.A., and Stack, M.S. 1996. Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the α2β1 integrin. Int. J. Cancer. 67:695-701.
20. Kenny, H.A., Krausz, T., Yamada, S.D., and Lengyel, E. 2007. Development of an organotypic peritoneal three-dimensional culture to study peritoneal attachment of ovarian cancer cells. Int. J. Cancer. 121:1463-1472.
21. Westerlund, A., Hujanen, E., Puistola, U., and Turpeenniemi-Hujanen, T. 1997. Fibroblasts stimulate human ovarian cancer cell invasion and expression of 72-kDa gelatinase A (MMP-2). Gynecol. Oncol. 67:76-82.
22. Koivunen, E., et al. 1999. Tumor targeting with a selective gelatinase inhibitor. Nat. Biotechnol. 17:768-774.
23. Hu, B., et al. 2003. Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2. Proc. Natl. Acad. Sci. U. S. A. 100:8904-8909.
24. Ramos-DeSimone, N., Moll, U., Quigley, J.P., and French, D.L. 1993. Inhibition of matrix metalloproteinase 9 activation by a specific monoclonal antibody. Hybridoma. 12:349-363.
25. Tam, E.M., Wu, Y., Butler, G., Stack, S., and Overall, C. 2002. Collagen binding properties of the membrane type-1 matrix metalloproteinase (MT1-MMP) hemopexin C domain. J. Biol. Chem. 277:39005-39014.
26. Coussens, L., Tinkle, C.L., Hanahan, D., and Werb, Z. 2000. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell. 103:481-490.
27. Autio-Harmainen, H., et al. 1993. Expression of 72 kilodalton type IV collagenase (gelatinase A) in benign and malignant ovarian tumors. Lab. Invest. 69:312-321.
28. Itoh, T., et al. 1998. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 58:1048-1051.
29. Yan, C., Wang, H., and Boyd, D. 2002. ATF3 represses 72-kDa type IV collagenase (MMP-2) expression by antagonizing p53- dependent transactivation of the collagenase promoter. J. Biol. Chem. 277:10804-10812.
30. Bian, J., and Sun, Y. 1997. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol. Cell. Biol. 17:6330-6338.
31. Modesitt, S.C., et al. 2001. In vitro and in vivo adenovirus-mediated p53 and p16 tumor supressor therapy in ovarian cancer. Clin. Cancer Res. 7:1765-1772.
32. Pletenpol, J.A., et al. 1994. Sequence-specific transcriptional activation is essential for growth supression by p53. Proc. Natl. Acad. Sci. U. S. A. 91:1998-2002.
33. Sawada, K., et al. 2007. C-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res. 67:1670-1680.
34. Carreiras, F., et al. 1999. Migration properties of the human ovarian adenocarcinoma cell line IGROV1: importance of αvβ3 integrins and vitronectin. Int. J. Cancer. 80:285-294.
35. Pierschbacher, M.D., Hayman, E.G., and Ruoslahti, E. 1985. The cell attachment determinant in fibronectin. J. Cell. Biochem. 28:115-126.
36. Cannistra, S.A., Ottensmeier, C., Niloff, J., Orta, B., and DiCarlo, J. 1995. Expression and function of β1 and αvβ3 integrins in ovarian cancer. Gynecol. Oncol. 58:216-225.
37. Krüger, A., et al. 2005. Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res. 65:3523-3526.
38. Boyd, R., and Balkwill, F. 1999. MMP-2 release and activation in ovarian carcinoma: the role of fibroblasts. Br. J. Cancer. 80:315-321.
39. Naylor, M.S., Stamp, G.W., Davies, B.D., and Balkwill, F.R. 1994. Expression and activity of MMPs and their regulators in ovarian cancer. Int. J. Cancer. 58:50-56.
40. Vikhanskaya, F., Erba, E., D'Incalci, M., and Broggini, M. 1994. Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. Nucleic Acids Res. 22:1012-1017.
41. Brader, K.R., et al. 1997. Adenovirus E1A expression enhances the sensitivity of an ovarian cancer cell line to multiple cytotoxic agents through an apoptotic mechanism. Clin. Cancer Res. 3:2017-2024.
42. Yaginuma, Y., and Westphal, H. 1992. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res. 52:4196-4199.
43. Hagiwara, K., McMenamin, M.G., and Harris, C.C. 1999. Mutational analysis of the p63/p73L/p51/p40/CUSP/Ket gene in human cancer cell lines using intronic primers. Cancer Res. 59:4165-4169.
44. Giannelli, G., et al. 1997. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science. 277:225-228.
45. Wang, H., et al. 2004. Tumor cell α3β1 integrin and vascular laminin-5 mediate pulmonary arrest and metastasis. J. Cell Biol. 164:935-941.
46. Huang, S., et al. 2002. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J. Natl. Cancer Inst. 94:1134-1142.
47. Coussens, L., et al. 1999. Inflammatory mast cells upregulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 13:1382-1397.
48. Vu, T.H., et al. 1998. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell. 93:411-422.
49. Mombaerts, P., et al. 1992. RAG-1 deficient mice have no mature B and T lymphocytes. Cell. 68:869-877.
50. Lounis, H., et al. 1994. Primary cultures of normal and tumoral human ovarian epithelium: a powerful tool for basic molecular studies. Exp. Cell Res. 215:303-309.
51. Lengyel, E., et al. 1995. Induction of Mr 92,000 type IV collagenase expression in a squamous cell carcinoma cell line by fibroblasts. Cancer Res. 55:963-967.
52. Ried, S., et al. 1999. Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor (HGF/SF). J. Biol. Chem. 274:16377-16386.
53. Pfaffl, M., et al. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e45.
54. 3A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter. Mol. Cell. Biol. 21:2118-2132.
55. Nie, L., Sasaki, M., and Maki, C.G. 2007. Regulation of p53 nuclear export through sequential changes in conformation and ubiquitination. J. Biol. Chem. 282:14616-14625.